Analysis of Valacyclovir Hydrochloride in Accordance with Japanese Pharmacopoeia

Importance of the Topic

Valacyclovir hydrochloride is a widely used antiviral agent against herpes infections and its precise quantification is critical for quality control and regulatory compliance. Robust analytical methods ensure safe and effective dosage forms and support pharmacopoeial standards.

Objectives and Study Overview

This study aimed to develop and validate a liquid chromatographic method using Shimadzu’s i-Series LC-2050C system in accordance with the Japanese Pharmacopoeia 18th edition. The focus was on purity tests (ii) and (iii) and the quantitative assay of valacyclovir hydrochloride under sub-ambient column temperatures.

Methodology

• Purity Test II: Confirmation of detection, system performance (theoretical plates and symmetry), and reproducibility (six injections) using a sample prepared at 4 mg/L.
• Purity Test III: Similar procedure with sample diluted in 0.05 mol/L HCl, assessing peak area ratio, column performance, and repeatability.
• Quantitative Assay: System suitability evaluated by plate count and symmetry on a CROWNPAK CR(+) column and RSD of six injections at 500 mg/L standard concentration.
• All analyses performed at 10–15 °C enabled by a low-temperature option kit to meet below-room-temperature requirements.

Used Instrumentation

• LC System: Shimadzu i-Series LC-2050C with low-temperature option.
• Column for Purity II: Shim-pack VP-Phenyl (250 × 4.6 mm, 5 µm) at 15 °C.
• Mobile Phases: A: 0.3% trifluoroacetic acid in water; B: 0.3% trifluoroacetic acid in methanol; gradient from 10% to 40% B over 35 min; flow rate 0.8 mL/min.
• Column for Purity III and Assay: CROWNPAK CR(+) (150 × 4.0 mm, 5 µm) at 10 °C with perchloric acid/methanol/water (5/30/965 v/v) at 0.7 mL/min.
• Detection: UV at 254 nm; injection volume 10 µL.

Main Results and Discussion

• Detection Limits and Peak Area Ratios: All measured area ratios fell within pharmacopoeial limits (4.92% for Purity II; 0.093% for Purity III).
• System Performance: Theoretical plate counts exceeded requirements by a wide margin (46 742 vs. ≥ 25 000 for Purity II; 1 941 and 1 849 vs. ≥ 700 for Purity III and assay).
• Symmetry Factors: Peaks remained well-shaped with symmetry ≤ 1.22 across all tests (criteria ≤ 2.0 for Purity II; ≤ 1.5 for Purity III and assay).
• Repeatability: Relative standard deviations were below 0.64% for purity tests and 0.02% for assay (criteria ≤ 2.0% and ≤ 1.0%, respectively), demonstrating high precision.

Benefits and Practical Applications

Valacyclovir analysis according to Japanese Pharmacopoeia is achieved with high sensitivity, precision, and reproducibility. The method’s compatibility with sub-ambient temperatures expands its usability in standard laboratories without climate control. This approach supports quality assurance in pharmaceutical manufacturing and regulatory compliance.

Future Trends and Possibilities

• Integration of automated temperature control modules for enhanced method robustness.
• Application of similar low-temperature LC strategies to other temperature-sensitive compounds.
• Adoption of advanced detectors (e.g., mass spectrometry) for simultaneous impurity profiling.
• Miniaturized and high-throughput systems for increased lab efficiency.

Conclusion

The i-Series LC-2050C method reliably meets Japanese Pharmacopoeia 18th edition requirements for valacyclovir hydrochloride. Sub-ambient column operation did not compromise sensitivity or precision, confirming the system’s suitability for routine antiviral drug analysis.